Atherosclerosis is a dynamic process in the human body. Many studies have evaluated atherosclerosis and its relationship with other systems in the body. Our perception of its pathogenesis is evolving with the introduction of new players in the game. It is no longer possible to consider the atherosclerosis as an independent process, unaffected by the liver and its function. Although several tasks performed by the liver, such as lipid metabolism, have been implicated in the pathogenesis of atherosclerosis, the role of other disorders of the liver (autoimmune diseases, viral hepatitis, and cirrhosis) are not fully understood. In this review, the most commonly encountered inflammatory liver diseases and their effects on atherosclerosis are discussed.
MartinA, LemonSM. Hepatitis A virus: from discovery to vaccines. Hepatology. 2006;43:S164–S172.
2.
TongMJ, el-FarraNS, GrewMI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis. 1995;171(suppl 1):S15–S18.
3.
JeongSH, LeeHS. Hepatitis A: clinical manifestations and management. Intervirology. 2010;53:15–19.
4.
ZhuJ, QuyyumiAA, NormanJE, . The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis. 2000;182:1583–1587.
5.
OngeyM, BrennerH, ThefeldW, . Helicobacter pylori and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study. Eur J Cardiovasc Prev Rehabil. 2004;11:471–476.
6.
BurnettMS, ZhuJ, MillerJM, . Effects of hepatitis A vaccination on atherogenesis in a murine model. J Viral Hepat. 2003;10:433–436.
7.
AuerJ, LeitingerM, BerentR, . Hepatitis A IgG seropositivity and coronary atherosclerosis assessed by angiography. Int J Cardiol. 2003;90:175–179.
8.
SzkloM, DingJ, TsaiMY, . Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Med (Hagerstown). 2009;10:747–751.
9.
CorradoE, RizzoM, TantilloR, . Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke. 2006;37:482–486.
10.
YangKC, ChenMF, SuTC, . Hepatitis B virus seropositivity is not associated with increased risk of carotid atherosclerosis in Taiwanese. Atherosclerosis. 2007;195:392–397.
11.
WangCH, ChenCJ, LeeMH, . Chronic hepatitis B infection and risk of atherosclerosis-related mortality: a 17-year follow-up study based on 22,472 residents in Taiwan. Atherosclerosis. 2010;211:624–629.
12.
TongDY, WangXH, XuCF, . Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus. World J Gastroenterol. 2005;11:1292–1296.
13.
IshizakaN, IshizakaY, TakahashiE, . Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation. 2002;105:1028–1030.
14.
FarciP, AlterHJ, WongD, . A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325:98–104.
15.
BarreraJM, BrugueraM, ErcillaMG, . Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21:639–644.
16.
MarcellinP. Hepatitis B and hepatitis C in 2009. Liver Int. 2009;29(suppl 1):1–8.
17.
AlyanO, KacmazF, OzdemirO, . Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J. 2008;72:1960–1965.
18.
ReardonMF, NestelPJ, CraigIH, . Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985;71:881–888.
19.
BoddiM, AbbateR, ChelliniB, . Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol. 2010;47:72–75.
20.
CarrenoV, BartolomeJ, CastilloI, . Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol. 2008;18:139–157.
21.
BiloraF, CampagnoloE, RinaldiR, . Carotid and femoral atherosclerosis in chronic hepatitis C: a 5-year follow-up. Angiology. 2008;59:717–720.
22.
IshizakaY, IshizakaN, TakahashiE, . Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J. 2003;67:26–30.
23.
ArcariCM, NelsonKE, NetskiDM, . No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis. 2006;43:e53–e56.
24.
TomiyamaH, AraiT, HiroseK, . Hepatitis C virus seropositivity, but not hepatitis B virus carrier or seropositivity, associated with increased pulse wave velocity. Atherosclerosis. 2003;166:401–403.
25.
VolzkeH, SchwahnC, WolffB, . Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis. 2004;174:99–103.
26.
TargherG, BertoliniL, PadovaniR, . Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007;46:1126–1132.
27.
EpsteinSE, ZhuJ, NajafiAH, . Insights into the role of infection in atherogenesis and in plaque rupture. Circulation. 2009;119:3133–3141.
28.
AdamE, MelnickJL, ProbtsfieldJL, . High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet. 1987;2:291–293.
29.
TargherG, ArcaroG. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–240.
30.
TargherG, BertoliniL, RodellaS, . Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–2121.
31.
TargherG, BertoliniL, PadovaniR, . Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010;53:713–718.
32.
TargherG, BertoliniL, PadovaniR, . Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325–1330.
33.
SookoianS, PirolaCJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49:600–607.
34.
VillanovaN, MoscatielloS, RamilliS, . Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–480.
35.
YilmazY, KurtR, YonalO, . Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis. 2010;211:182–186.
36.
MatteoniCA, YounossiZM, GramlichT, . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419.
37.
AdamsLA, LympJF, StSauver J, . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.
38.
SoderbergC, StalP, AsklingJ, . Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602.
39.
TargherG, DayCP, BonoraE. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–1350.
40.
ChalasaniN, DeegMA, CrabbDW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1497–1502.
41.
YesilovaZ, YamanH, OktenliC, . Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2005;100:850–855.
42.
KugelmasM, HillDB, VivianB, . Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413–419.
43.
HaukelandJW, DamasJK, KonopskiZ, . Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–1174.
44.
MussoG, GambinoR, DurazzoM, . Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 2005;42:1175–1183.
45.
TargherG, BertoliniL, ScalaL, . Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22:1354–1358.
MussoG, GambinoR, De MichieliF, . Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909–916.
54.
MussoG, CassaderM, GambinoR, . Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. Hepatology. 2006;43:1169–1170.
55.
MarschangP, GotschC, KirchmairR, . Postprandial, but not postabsorptive low-density lipoproteins increase the expression of intercellular adhesion molecule-1 in human aortic endothelial cells. Atherosclerosis. 2006;186:101–106.
56.
AlkhouriN, TamimiTA, YerianL, . The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci. 2010;55:2644–2650.
57.
DonnellyKL, SmithCI, SchwarzenbergSJ, . Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351.
58.
AdielsM, TaskinenMR, PackardC, . Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755–765.
SorokinA, BrownJL, ThompsonPD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194:293–299.
61.
KaplanMM, GershwinME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–1273.
62.
SelmiC, InvernizziP, KeeffeEB, . Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol. 2004;38:264–271.
63.
ParesA, RodesJ. Natural history of primary biliary cirrhosis. Clin Liver Dis. 2003;7:779–794.
64.
StojakovicT, ClaudelT, Putz-BankutiC, . Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis. 2010;209:178–183.
65.
JahnCE, SchaeferEJ, TaamLA, . Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. 1985;89:1266–1278.
66.
CrippinJS, LindorKD, JorgensenR, . Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?Hepatology. 1992;15:858–862.
67.
HiraokaH, YamashitaS, MatsuzawaY, . Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology. 1993;18:103–110.
68.
ChangPY, LuSC, SuTC, . Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45:2116–2122.
69.
Baldo-EnziG, BaiocchiMR, GrottoM, . Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects. Dig Dis Sci. 1988;33:1201–1207.
70.
LongoM, CrosignaniA, BattezzatiPM, . Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265–269.
71.
VanDam GM, GipsCH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol. 1997;32:77–83.
72.
TanakaM, FukuiM, TomiyasuK, . Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis. 2009;206:287–291.
73.
VitekL, NovotnyL, SperlM, . The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis. 2006;21:408–414.
74.
DudnikLB, AzyzovaOA, SolovyovaNP, . Primary biliary cirrhosis and coronary atherosclerosis: protective antioxidant effect of bilirubin. Bull Exp Biol Med. 2008;145:18–22.
75.
KarasuZ, MindikogluAL, Van ThielDH. Cardiovascular problems in cirrhotic patients. Turk J Gastroenterol. 2004;15:126–132.
76.
VanecekR. Atherosclerosis and cirrhosis of the liver. Bull World Health Organ. 1976;53:567–570.
77.
HowellWL, ManionWC. The low incidence of myocardial infarction in patients with portal cirrhosis of the liver: A review of 639 cases of cirrhosis of the liver from 17,731 autopsies. Am Heart J. 1960;60:341–344.
78.
MarchesiniG, RonchiM, ForlaniG, . Cardiovascular disease in cirrhosis-a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol. 1999;94:655–662.
79.
TamuraM, KiharaY, OtsukiM. Carotid intima-media thickness in patients with liver cirrhosis associated with diabetes mellitus. Diabetes Res Clin Pract. 2007;78:176–181.
80.
KadayifciA, TanV, UrsellPC, . Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49:595–599.
